QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
Log in
NASDAQ:CTSO

Cytosorbents Stock Forecast, Price & News

$9.62
+0.04 (+0.42 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.28
Now: $9.62
$9.70
50-Day Range
$7.97
MA: $8.61
$9.58
52-Week Range
$3.60
Now: $9.62
$11.74
Volume278,067 shs
Average Volume384,704 shs
Market Capitalization$415.35 million
P/E RatioN/A
Dividend YieldN/A
Beta0.36
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors; and VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; K+ontrol for treatment of severe hyperkalemia with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a development-stage extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.
Cytosorbents logo

MarketRank

Overall MarketRank

1.69 out of 5 stars

Medical Sector

218th out of 1,922 stocks

Surgical & Medical Instruments Industry

20th out of 168 stocks

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTSO
CUSIPN/A
Phone732-329-8885
Employees153
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$24.95 million
Book Value$0.11 per share

Profitability

Net Income$-19,270,000.00

Miscellaneous

Market Cap$415.35 million
Next Earnings Date3/4/2021 (Estimated)
OptionableOptionable
$9.62
+0.04 (+0.42 %)
(As of 01/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CTSO News and Ratings via Email

Sign-up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions

How has Cytosorbents' stock been impacted by COVID-19 (Coronavirus)?

Cytosorbents' stock was trading at $4.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CTSO stock has increased by 101.7% and is now trading at $9.62.
View which stocks have been most impacted by COVID-19
.

Is Cytosorbents a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cytosorbents stock.
View analyst ratings for Cytosorbents
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Cytosorbents?

Wall Street analysts have given Cytosorbents a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cytosorbents wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Phillip Chan's approval rating as Cytosorbents' CEO?

2 employees have rated Cytosorbents CEO Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among Cytosorbents' employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Cytosorbents' next earnings date?

Cytosorbents is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Cytosorbents
.

How were Cytosorbents' earnings last quarter?

Cytosorbents Co. (NASDAQ:CTSO) posted its quarterly earnings data on Wednesday, November, 4th. The medical research company reported ($0.02) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.07. The medical research company had revenue of $10.55 million for the quarter, compared to the consensus estimate of $9.53 million. Cytosorbents had a negative net margin of 30.45% and a negative trailing twelve-month return on equity of 34.37%.
View Cytosorbents' earnings history
.

What guidance has Cytosorbents issued on next quarter's earnings?

Cytosorbents updated its fourth quarter 2020 Pre-Market earnings guidance on Tuesday, January, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $11.8-11.8 million, compared to the consensus revenue estimate of $10.81 million.

What price target have analysts set for CTSO?

6 equities research analysts have issued 1 year price objectives for Cytosorbents' stock. Their forecasts range from $14.00 to $17.00. On average, they anticipate Cytosorbents' share price to reach $15.33 in the next twelve months. This suggests a possible upside of 59.4% from the stock's current price.
View analysts' price targets for Cytosorbents
or view Wall Street analyst' top-rated stocks.

Who are some of Cytosorbents' key competitors?

What other stocks do shareholders of Cytosorbents own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include NanoViricides (NNVC), Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Who are Cytosorbents' key executives?

Cytosorbents' management team includes the following people:
  • Dr. Phillip P. Chan, CEO, Pres & Director (Age 51, Pay $549.64k)
  • Mr. Vincent J. Capponi M.S., MS, Pres & COO (Age 63, Pay $420.8k)
  • Ms. Kathleen P. Bloch CPA, M.B.A., MBA, CPA, CFO & Sec. (Age 66, Pay $373.9k)
  • Dr. Christian Steiner M.D., Exec. VP of Sales & Marketing
  • Mr. Christopher Cramer, VP of Bus. Devel.
  • Dr. Efthymios N. Deliargyris M.D., FACC, FESC, FSCAI, Chief Medical Officer (Age 53)
  • Dr. Robert H. Bartlett, Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 82)

What is Cytosorbents' stock symbol?

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

How do I buy shares of Cytosorbents?

Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cytosorbents' stock price today?

One share of CTSO stock can currently be purchased for approximately $9.62.

How big of a company is Cytosorbents?

Cytosorbents has a market capitalization of $415.35 million and generates $24.95 million in revenue each year. The medical research company earns $-19,270,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. Cytosorbents employs 153 workers across the globe.

What is Cytosorbents' official website?

The official website for Cytosorbents is www.cytosorbents.com.

How can I contact Cytosorbents?

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.